NCT04976036 - Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Telangiectasia, Hereditary Hemorrhagic

Interventions

DRUG

Nintedanib

150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)

DRUG

Placebo

150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)

Trial Locations (1)

RECRUITING

Respiratory medicine Department, Lausanne University Hospital, Lausanne